Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2011

View Archived Issues

Trophos discloses new first-in-human data on TRO-40303

U.S. government contracts Elusys to develop anthrax antitoxin for pre- and postexposure prophylaxis

Korean University links putative oncogene to development of hepatocellular carcinoma

Genentech discloses new brain-penetrant PI3K inhibitors

Long-term safety of alipogene tiparvovec evaluated in patients with lipoprotein lipase deficiency

Phase Ia trial assesses CPG-7909-adjuvanted BioThrax

GlaxoSmithKline patents novel therapeutics for hepatitis C

New inhibitors of Sn1-specific diacylglycerol lipases reported

TransTech Pharma claims new RAGE antagonists

Novel IL-1 beta inhibitors disclosed by Ampla Pharmaceuticals

Affitech generates new antibodies against chemokine CXCR4 receptor

First triptan for migraine in adolescents approved in Canada

Two new companies spun out of Amira Pharmaceuticals

European Commission grants orphan drug status to sirolimus

Ongoing ALTTO study modified

Takeda initiates phase III program for TAK-875 in Japan

Peregrine Pharmaceuticals completes enrollment in phase II bavituximab trial

EpiCept receives definitive FDA guidance on design of Cepilene registration trial

Taiho sets date for Japanese launch of Zolinza

Sucampo and Numab to collaborate in discovery of high-affinity antibodies

BIBF-1120 obtains Japanese orphan drug status

Roche beings phase I trial of investigational drug for Down syndrome

Janssen Biotech receives complete response letter from FDA regarding sBLA for Simponi

Silence Therapeutics and InteRNA Technologies enter miRNA agreement

Repros Therapeutics to submit IND for vaginal formulation of Proellex

New biomarker to predict clinical outcome of sorafenib-treated hepatocellular carcinoma

Diamyd receives NIH grant to develop NTDDS-based drug candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Harbour Biomed closes busy year with $1B+ BMS deal
BioWorld
Harbour Biomed has added another collaboration to its end-of-year dealmaking, this time with Bristol Myers Squibb Co. (BMS) to develop multispecific antibodies....
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...